Ritlecitinib 50 mg

Phase 3

PFIZER (PFE)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '26

PFEPhase 2$143.7B

Ritlecitinib 50 mg Phase 2 Est. Readout

Ritlecitinib 50 mg• Chronic Spontaneous Urticaria200

Q4 2026~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in Chronic Spontaneous Urticaria

JSPRBriquilimab

Phase 2

View Full Landscape

Drug Information

Target Indication

Chronic Spontaneous Urticaria

Clinical Trial

NCT07219615

Last updated: 4/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts